Evidence map›Paper›PMID 19306895›Full record

ReviewPharmacology & therapeutics2009

Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.

Emily J Tsai, David A Kass

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacology & therapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05711719 (Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction), which is not on this map. Cited by 188 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
188citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05711719 phase2completednot on this mapstarted 2023, after this paper: background citation

Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction

TypeinterventionalSponsorJohns Hopkins UniversityRan2023 to 2025Enrolled45ConditionsMetabolic Syndrome, Coronary Microvascular DysfunctionArmsVericiguat, Placebo
3 · Its place in the literature

Who cites it

188 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Temporal Dissociation of Impaired Glucose Tolerance, Adipose Lipid Remodeling and Endothelial Dysfunction in Aorta After HFD Withdrawal.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  12. Vericiguat: A New Horizon for Heart Failure Treatment.Reviews in cardiovascular medicine · 2026
    Review
  13. Article
  14. Article
  15. Review
  16. Soluble guanylyl cyclase, the NO receptor, drives vasorelaxation via endothelial S-nitrosation.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article

128 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Emily J TsaiDivision of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA.
David A Kass

Funding

PATHOPHYSIOLOGY OF MYOCARDIAL DISEASEST32HL007227 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Chulan Kwon, WENDY S POST · 1985 to 2026
$21.2M
Regulation of Cardiac Stress Responses by PDE5aR01HL089297 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI KASS, DAVID ALAN · 2008 to 2011
$1.8M
NHLBI NIH HHS R01 HL089297NHLBI NIH HHS T32 HL007227
6 · The paper itself

Abstract

Cyclic guanosine 3',5'-monophosphate (cGMP) mediates a wide spectrum of physiologic processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at any step of the cascade - cGMP synthesis, effector activation, or catabolism - have been implicated in numerous cardiovascular diseases, ranging from hypertension to atherosclerosis to cardiac hypertrophy and heart failure. In this review, we outline each step of the cGMP signaling cascade and discuss its regulation and physiologic effects within the cardiovascular system. In addition, we illustrate how cGMP signaling becomes dysregulated in specific cardiovascular disease states. The ubiquitous role cGMP plays in cardiac physiology and pathophysiology presents great opportunities for pharmacologic modulation of the cGMP signal in the treatment of cardiovascular diseases. We detail the various therapeutic interventional strategies that have been developed or are in development, summarizing relevant preclinical and clinical studies.

Indexed as

AnimalsCardiovascular AgentsCardiovascular DiseasesCardiovascular Physiological PhenomenaCyclic GMPHumansSignal TransductionCardiovascular AgentsCyclic GMP

Identifiers

PMID19306895
PMCPMC2709600

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.